Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, D.C. 20515

Secretary of the Senate Office of Public Records 232 Hart Building Washington, D.C. 20510

SECRETARY OF

02 FEB 13

LOBBYING REPORT

Lobby Disclosure Act of 1995 (Section 5) — All Filers Are Required To Complete This Page

1. Registrant Name		
Hogan & Hartson L.L.P.		
2. Address		
Principal Place of Business (if different from line 2) City State/2	Zip (or Country)	
4. Contact Name Telephone Maruyama, Warren H. 202-637-5709 WHMaruyama@HHLAW.com	E-mail (optional) 5. Senate ID # 18422-1611	
7. Client name Self Pharmaceutical Research Manufacturers of America (PhRMA)	6. House ID # 30470157	
10. Check if this is a Termination Report □ ⇒ Termination INCOME OR EXPENSES — Complete Either Line		
12. Lobbying Firms	. 13. Organizations	
INCOME relating to lobbying activities for this reporting period was: Less than \$10,000	EXPENSES relating to lobbying activities for this reporting were: Less than \$10,000	
\$10,000 or more \square \Rightarrow \$\frac{340,000}{Income (nearest \$20,000)}\$ Provide a good faith estimate, rounded to the nearest \$20,000, of all	\$10,000 or more	
lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to inconcerning method. See instructions for description of options of the concerning method.	
	☐ Method A. Reporting amounts using LDA definition	
	Method B. Reporting amounts under section 603. Internal Revenue Code	
	Method C. Reporting amounts under section 162(e) Revenue Code	
Signature W4	Date	
Printed Name and Title Maruyama, Warren H. Partner	/ /	

Registrant Name	Hogan & Hartson L.L.P.	Client Name	Pharmaceutical Research Man of America (PhRMA)
engaged in lobbyin		the reporting period. Usi	e general issue areas in which t ing a separate page for each c
15. General issue a	area code <u>TRD</u> (one po	er page)	
and regulatory issue	ing issues de, U.SJapan Enhanced De-Reg es; Taiwan patent term protection omotion Authority (TPA).		
U.S. House of Repr U.S. Senate; Office of U.S. Trad Department of Com Department of State NEC/NSC; U.S. Embassy (Tok	le Representative; nmerce; e;		None
	Name	Covered Offici	al Position (if applicable)
Archibald, Jeanne	S.	Partner	
Chang, Irene F.		Associate	
Maruyama, Warre	n H.	Partner	
		•	
19. Interest of each	foreign entity in the specific iss	sues listed on line 16 above	☑ Check if None
Signature	W H, Filing #d94c2c9b-55e6-40bc-adk	b4-56dc1aa72c4e - Page 3 of 1	0

Printed Name and Title_	Maruyama, Warren H.	Partner		
LD-2 (REV. 6/98)			-	

Registrant Name	Hogan & Hartson L.L.P.	Client Name	Pharmaceutical Research Man of America (PhRMA)
engaged in lobbying	FIVITY. Select as many codes and on behalf of the client during to uested. Attach individual page(s)	he reporting period. Usi	
15. General issue a	area code <u>MMM</u> (one p	er page)	
16. Specific lobby	ing issues		
	Prescription Drug and Modernizat re prescription drug benefits	ion Act of 2001 and other	r legislation
17. House(s) of Co	ongress and Federal agencies conta	acted ☑ Check if N	None
•			
18. Name of each	individual who acted as a lobbyist	in this issue area	
•	Name	Covered Offici	al Position (if applicable)
Vickery, Ann Morgan			
INTERNATION OF THE PROPERTY OF			•
ATTICLE TO THE STATE OF THE STA			NAME OF THE OWNER OWNER OF THE OWNER OWNE
19. Interest of each	n foreign entity in the specific issu	es listed on line 16 above	☑ Check if None
		۵	
Signature	M, M		

•>

Printed Name and Title Manukama Warren H Partner Filing #d94c2c9b-55e6-40bc-adb4-56dc1aa72c4e - Page 5 of 10

LD-2 (REV. 6/98)

Registrant Name Hogan & Hartson L.L.P.	Client Name	Pharmaceutical Research Man of America (PhRMA)
LOBBYING ACTIVITY. Select as many of engaged in lobbying on behalf of the client of information as requested. Attach individual p	turing the reporting period. Usi	
15. General issue area code HCR (one per page)	
16. Specific lobbying issues		
S. 812, Greater Access to Affordable Pharmach H.R. 3448, Public Health Security and Biotern S. 1715/S. 1765 Bioterrorism Preparedness Access Access Access to Affordable S. 812/H.R. 1862, Greater Access to Affordab	orism Response Act of 2001 et of 2001	
17. House(s) of Congress and Federal agencies U.S. Senate U.S. House of Representatives Department of Health and Human Services		Jone
18. Name of each individual who acted as a lo	obbyist in this issue area	
Name	Covered Officia	al Position (if applicable)
Beier, David W.	Chief Domestic Policy	Advisor for Vice President Gor
Bultana, Lance D.		
19. Interest of each foreign entity in the specif	ic issues listed on line 16 above	☑ Check if None
Signature LUH Filing #d94c2c9b-55e6-40	bc-adb4-56dc1aa72c4e - Page 7 of 1	0

Printed Name and Title Maruyama, Warren H. Partner

LD-2 (REV. 6/98)

Registrant Name	Hogan & Hartson	L.L.P.	Client Name		ceutical Research Man rica (PhRMA)
Information Upd	ate Page — Comple	ete ONLY where	e registration inform	ation has	changed.
20. Client new add	dress				
21. Client new pri	ncipal place of busin	ess (if different t	from line 20)		
City			State/Zip (or	Country	
•	lescription of client's	business or activ	_ ,	country)	
LOBBYIST UPD 23. Name of each Chang, Irene F.		individual who is	s no longer expected t	o act as a	lobbyist for the client
ISSUE UPDATE 24. General lobby	ing issues previously	reported that no	longer apply	•	
	RGANIZATIONS ving affiliated organic	zation(s)			
N	ame		Address		Principal Place of B (city and state or co
26. Name of each	previously reported o	organization that	is no longer affiliated	l with the	registrant or client
FOREIGN ENTI 27. Add the follow	TIES ving foreign entities				·
Name		Address	Principal place of busi and state or coun		Amount of contribution for lobbying activities
28. Name of each client or affilia	previously reported f ted organization	oreign entity tha	t no longer owns, or o	controls, g	or is affiliated with the
Signature	was bo				

Printed Name and Title Manual Warner Bound Title House Bound Briling #d94c2c9b-55e6-40bc-adb4-56dc1aa72c4e - Page 9 of 10

TITITOG TATIFO GITG TITIO IVIAIUNAIIIA, VYAITCII II. FAILIICI

LD-2 (REV. 6/98)